Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

The top-line results of the APOLLOE4 trial showed that valitramiprosate (ALZ-801) was unable to slow down cognitive decline ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

The binding affinity of an antibody to its antigen is largely determined ... two of the residues identified by alanine scanning are located on a CDR loop whereas the other two are in the ...

The potential of monoclonal antibodies (mAbs) as therapies is indisputable. The current mAbs market is expected to be around ~USD 150 billion. In 2021, five out of the top 10 selling drugs were ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) wh ...

The US Food and Drug Administration announced Thursday that it will be phasing out a requirement that monoclonal antibodies and other drugs be tested on animals, saying in a news release that ...

The test doesn't detect the virus itself but instead detects antibodies—called immunoglobulin G (IgG)—produced by the immune system in response to the virus. A positive test result indicates that you ...

The latest White & Case and Queen Mary University international arbitration survey is the biggest yet with 2,400 respondents, with pre-publication teasers released during Paris Arbitration Week ...